Overview

• SARU confirmed the Springbok prop returned an adverse analytical finding during SAIDS random testing.
• The union says the substance was prescribed by a specialist and taken under the team doctor’s supervision, and that the player acted in good faith.
• SAIDS CEO Khalid Galant said there is no provisional suspension and noted that non-selection for the New Zealand tour was a SARU decision.
• A disciplinary hearing date is expected to be set this week by the player’s counsel, SAIDS and an independent panel.
• Rassie Erasmus said the tour omission was to protect the player from distraction as he assembles his legal defence, and reports say he has not requested B‑sample testing.